Age-dependent likelihood of in situ thrombosis in secondary pulmonary hypertension

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 3, 2004, Pages 217-223

  Caramuru, Lúcia H ^a   Maeda, Nair Y ^b   Bydlowski, Sérgio P ^b   Lopes, Antonio Augusto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Pró Sangue Foundation Institute for Investigation in Immunology Iii INCT   (Brazil)

Author keywords

Endothelial dysfunction; Hypoxia; Intravascular coagulation; Pulmonary hypertension; Thrombosis

Indexed keywords

D DIMER; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGE; ANGIOGRAPHY; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EISENMENGER COMPLEX; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; FEMALE; HEMATOCRIT; HUMAN; LUNG ARTERY PRESSURE; LUNG ARTERY THROMBOSIS; MALE; OXYGEN SATURATION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

EID: 3242769144     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000303     Document Type: Article

References (22)

1. Rabinovitch M. Pulmonary hypertension: Updating a mysterious disease. Cardiovasc Res 1997;34:268.
2. The International consortium, Lane KB, Machado RD, et al. Heterozygous germline mutations in a TGF-β receptor, BMPR2, are the cause of familial primary pulmonary hypertension. Nat Genet 2000;26:81.
3. Vongpatanasin W, Brickner ME, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128:745.
4. Cacoub P, Karmochkine M, Dorent R, et al. Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 1996;101:160.
5. Huber K, Beckmann R, Frank H, et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994;150:929.
6. Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996;19:549.
7. Welsh CH, Hassell KL, Badesch DB, et al. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996;110:710.
8. Lopes AA, Caramurú LH, Maeda NY. Endothelial dysfunction associated with chronic intravascular coagulation in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2002;8:353.
9. Takahashi H, Ito S, Hanano M, et al. Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992;41:32.
10. Wagenvoort CA, Mulder GH. Thrombotic lesions in primary plexogenic arteriopathy. Chest 1993;103:844.
11. Rosenzweig EB, Barst R. Eisenmenger's syndrome: Current management. Prog Cardiovasc Dis 2002;45:129.
12. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993;87(suppl):138.
13. Saha A, Balakrishnan KG, Jaiswal PK, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994;45:1999.
14. Moser KM, Auger WR, Fedullo PF, et al. Chronic thromboembolic pulmonary hypertension: Clinical picture and surgical treatment. Eur Respir J 1992;5:334.
15. Simonneau G, Azarian R, Brenot F, et al. Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. Chest 1995;107:52S.
16. Rich S, ed. Primary pulmonary hypertension. Executive Summary from the World Symposium. Primary Pulmonary Hypertension; France, 1998. [WHO web site]. Available at: www.who.int/ncd/cvd/pph-htm〉 1998.
17. Maeda NY, Bydlowski SP, Lopes AAB. Platelet GP IIb/IIIa and non-receptor tyrosine kinases pp60 c-src and pp125FAK in patients with advanced pulmonary hypertension. Eur Heart J 2002;4:113.
18. Caramurú LH, Soares RPS, Maeda NY, et al. Hypoxia and altered platelet behaviour influence von Willebrand factor multimeric composition in secondary pulmonary hypertension. Clin Appl Thromb Hemost 2003;9:251.
19. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:1.
20. Dorfmüller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165:534.
21. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001;86:298.
22. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782.